Lamotrigine Tablet, Film Coated, Extended Release
Product Images NDC 82804-022

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 82804-022). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg Tab (100mg Picture)

Lamotrigine extended-release 50 mg film-coated tablet imprinted with 'Y33' on one side. Oral dosage form manufactured by Proficient Rx LP.*

FDA Label Image

200 mg Tab (200mg Picture)

The image shows the tablet imprint "Y34", which identifies it as lamotrigine extended-release 50 mg. The tablet is film-coated and intended for oral administration. This specific dosage form is provided by Proficient Rx LP under NDC 82804-022.*

FDA Label Image

250 mg Tab (250mg Picture)

Lamotrigine extended-release 50 mg film-coated tablet, imprinted with 'Y35'. This oral prescription medication is labeled by Proficient Rx LP. The tablet is oval-shaped and white.*

FDA Label Image

25 mg Tab (25mg Picture)

The image shows a white, round, film-coated extended-release tablet engraved with "Y31" on one side. The tablet corresponds to lamotrigine extended-release 50 mg, a human prescription drug by Proficient Rx LP.*

FDA Label Image

300 mg Tab (300mg Picture)

Identification imprint on lamotrigine extended-release 50 mg film-coated tablet displays 'Y36' within an oval shape.*

FDA Label Image

50 mg Tab (50mg Picture)

Lamotrigine extended-release 50 mg film-coated tablet marked with 'Y32' on one side. The round, white tablet is designed for oral administration and is manufactured by Proficient Rx LP.*

FDA Label Image

Figure 1. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (primary Generalized Tonic-clonic Seizures Study) (Figure 1)

A responder rate curve graph comparing lamotrigine extended-release (N=70) to placebo (N=73). The vertical axis shows responder rate from worsening to improvement, and the horizontal axis shows the percent of patients from 0 to 100. The lamotrigine group generally shows higher responder rates than placebo across patient percentages.*

FDA Label Image

Figure 2. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (partial-onset Seizure Study) (Figure 2)

A cumulative responder rate graph comparing lamotrigine extended-release (N=116) and placebo (N=120). The x-axis shows the percent of patients from 0 to 100, and the y-axis shows the responder rate from worsening to equal or greater improvement. Two lines represent lamotrigine and placebo response rates over the patient percentage.*

FDA Label Image

Chemical Structure (Graphic 01)

Chemical structure of lamotrigine, showing its molecular framework with chlorine atoms, amino groups, and a triazine ring.*

FDA Label Image

82804-022-30 (Label 50mg 30tablets)

Label for Lamotrigine 50 mg extended-release (E.R.) tablets by Proficient Rx LP, containing 30 tablets. The label includes drug identification details, a caution to verify the product dispensed, storage instructions (20°-25°C), and manufacturer information (Yiling Pharmaceutical Ltd, China). Tablets are described as green, round, biconvex, film-coated with 'Y32' printed on one side.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.